{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:02:07Z","timestamp":1789682527116,"version":"4.0.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Pancreatic ductal adenocarcinoma (PDAC) continues to exhibit resistance to immunotherapy. In this study, we evaluated the efficacy of combining immunotherapy with chemotherapy for the treatment of advanced pancreatic cancer. Additionally, we employed a multimodal analytical approach to elucidate the immune landscape and conduct transcriptomic profiling in PDAC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective analysis was conducted on the clinical data of 52 patients diagnosed with advanced PDAC who underwent a combined treatment regimen of immunotherapy and chemotherapy. The study evaluated the objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). To characterize the immune landscape in treatment-naive pancreatic ductal adenocarcinoma (PDAC) tumors and in the systemic circulation, flow cytometry, multiplex immunohistochemistry (mIHC), and whole transcriptome sequencing were employed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The study reported an ORR of 32.7%, a DCR of 67.3%, and a 6-month PFS rate of 38.5%, with a median PFS of 5.5 months. Patients treated with a combination of immunotherapy and gemcitabine achieved the longest PFS. The first-line treatment cohort exhibited a significantly higher DCR (79.3% vs. 52.2%, P = 0.038) and a longer median PFS (6.6 vs. 3.5 months, P = 0.032) compared to the second-line treatment cohort. The efficacy of treatment varied depending on the drug combinations used. Flow cytometry analysis revealed a greater frequency of CD45- CD64+ cells in the peripheral blood of patients with progressive disease (PD) compared to those with a partial response (PR). Multiplex immunofluorescence (MIF) analysis indicated an increased intratumoral infiltration of CD8+ T cells and CD137+ CD8+ T cells in patients with PR. Whole transcriptome sequencing (WTSS) identified key genes involved in immune regulation, signal transduction, and digestive function. Hemopexin (HPX) and regulatory factor X-associated protein (RFXAP) were upregulated in PR patients and showed a positive correlation with survival, whereas Interleukin-6 (IL-6) expression was linked to poor prognosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These findings indicate that immunochemotherapy shows potential for the treatment of advanced PDAC. Our study elucidates the immune landscape associated with PDAC and provides critical insights for the identification of prospective therapeutic targets, which could guide the development of innovative combination immunotherapy strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1673098","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:33:34Z","timestamp":1759383214000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Multi-omics analyses inform mechanisms of immunotherapy response in pancreatic cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Mengyao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yecheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dapeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caihua","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01829-9","article-title":"Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial","volume":"28","author":"Padr\u00f3n","year":"2022","journal-title":"Nat Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.34133\/research.0600","article-title":"Crosstalk between gut microbiota and cancer immunotherapy: present investigations and future perspective","volume":"8","author":"Tang","year":"2025","journal-title":"Res (Wash D C)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.ccell.2020.08.004","article-title":"Challenges and opportunities for pancreatic cancer immunotherapy","volume":"38","author":"Bear","year":"2020","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00369-2","article-title":"Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b\/2 trial","volume":"23","author":"Reiss","year":"2022","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00286-2","article-title":"Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial","volume":"22","author":"Zhu","year":"2021","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.1588","article-title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: A phase 2 randomized clinical trial","volume":"5","author":"O\u2019Reilly","year":"2019","journal-title":"JAMA Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S267260","article-title":"Immunotherapy in combination with well-established treatment strategies in pancreatic cancer: current insights","volume":"14","author":"Kole","year":"2022","journal-title":"Cancer Manag Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S349442","article-title":"The efficacy and safety of PD-1 inhibitors combined with nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine in the first-line treatment of advanced pancreatic cancer: A retrospective monocentric study","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancer Manag Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e007883","DOI":"10.1136\/jitc-2023-007883","article-title":"Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)","volume":"12","author":"Callahan","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jso.26359","article-title":"Pancreas cancer: Therapeutic trials in metastatic disease","volume":"123","author":"Smithy","year":"2021","journal-title":"J Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.038","article-title":"Broadening the impact of immunotherapy to pancreatic cancer: challenges and opportunities","volume":"156","author":"Balachandran","year":"2019","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320726","article-title":"Comprehensive characterisation of pancreatic ductal adenocarcinoma with microsatellite instability: histology, molecular pathology and clinical implications","volume":"70","author":"Luchini","year":"2021","journal-title":"Gut"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.968360","article-title":"4-1BB: A promising target for cancer immunotherapy","volume":"12","author":"Kim","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ccell.2022.10.001","article-title":"Multi-omic analyses of changes in the tumor microenvironment of pancreatic adenocarcinoma following neoadjuvant treatment with anti-PD-1 therapy","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"B23","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1053\/j.gastro.2023.05.036","article-title":"Spatially resolved multi-omics single-cell analyses inform mechanisms of immune dysfunction in pancreatic cancer","volume":"165","author":"Yousuf","year":"2023","journal-title":"Gastroenterology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.ccell.2025.06.020","article-title":"Integrated single-cell and spatial transcriptomics uncover distinct cellular subtypes involved in neural invasion in pancreatic cancer","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell"},{"key":"B25","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1186\/s12967-025-06711-z","article-title":"Multi-omics integration and machine learning uncover molecular basal-like subtype of pancreatic cancer and implicate A2ML1 in promoting tumor epithelial-mesenchymal transition","volume":"23","author":"Ge","year":"2025","journal-title":"J Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-25-0387","article-title":"Neoadjuvant immunotherapy promotes the formation of mature tertiary lymphoid structures in a remodeled pancreatic tumor microenvironment","author":"Sidiropoulos","year":"2025","journal-title":"Cancer Immunol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adc9245","article-title":"Circulating hemopexin modulates anthracycline cardiac toxicity in patients and in mice","volume":"8","author":"Liu","year":"2022","journal-title":"Sci Adv"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108181","article-title":"Scavenging of labile heme by hemopexin is a key checkpoint in cancer growth and metastases","volume":"32","author":"Canesin","year":"2020","journal-title":"Cell Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8256314","article-title":"Single-cell sequencing identifies the heterogeneity of CD8+ T cells and novel biomarker genes in hepatocellular carcinoma","volume":"2022","author":"Wang","year":"2022","journal-title":"J Healthc Eng"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-024-00572-9","article-title":"Age-, sex- and proximal-distal-resolved multi-omics identifies regulators of intestinal aging in non-human primates","volume":"4","author":"Wang","year":"2024","journal-title":"Nat Aging"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2024.1403587","article-title":"Prognostic value of four immune-related genes in lower-grade gliomas: a biomarker discovery study","volume":"15","author":"Wang","year":"2024","journal-title":"Front Genet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-014-1638-4","article-title":"Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer","volume":"64","author":"Surmann","year":"2015","journal-title":"Cancer Immunol Immunother"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2024.02.002","article-title":"Explainable cancer factors discovery: Shapley additive explanation for machine learning models demonstrates the best practices in the case of pancreatic cancer","volume":"24","author":"Su","year":"2024","journal-title":"Pancreatology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1038\/s41419-020-03019-2","article-title":"Fisetin inhibits proliferation of pancreatic adenocarcinoma by inducing DNA damage via RFXAP\/KDM4A-dependent histone H3K36 demethylation","volume":"11","author":"Ding","year":"2020","journal-title":"Cell Death Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e007530","DOI":"10.1136\/jitc-2023-007530","article-title":"New perspectives in cancer immunotherapy: targeting IL-6 cytokine family","volume":"11","author":"Soler","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100878","article-title":"CD8+ T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108315","article-title":"Endothelial progenitor cells in the host defense response","volume":"241","author":"Shi","year":"2023","journal-title":"Pharmacol Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2022.0045","article-title":"IL-6 Accelerates the Proliferation and Metastasis of Pancreatic Cancer Cells via the miR-455-5p\/IGF-1R Axis","volume":"39","author":"Zhang","year":"2024","journal-title":"Cancer Biother Radiopharm"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1408770","article-title":"Gut microbiota and pancreatic cancer risk, and the mediating role of immune cells and inflammatory cytokines: a Mendelian randomization study","volume":"15","author":"Chen","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e163022","DOI":"10.1172\/jci.insight.163022","article-title":"Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer","volume":"8","author":"Kitamura","year":"2023","journal-title":"JCI Insight"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217620","article-title":"Irreversible electroporation combined with PD-L1\/IL-6 dual blockade promotes anti-tumor immunity via cDC2\/CD4+T cell axis in MHC-I deficient pancreatic cancer","volume":"617","author":"Wu","year":"2025","journal-title":"Cancer Lett"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673098\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T05:33:34Z","timestamp":1759383214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1673098\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2025.1673098"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1673098","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"article-number":"1673098"}}